Safety and immunogenicity of an optimized self-replicating RNA platform for low dose or single dose vaccine applications: a randomized, open label Phase I study in healthy volunteers

C Christian J. Maine S Shigeki J. Miyake-Stoner D Darina S. Spasova G Gaelle Picarda A Annie C. Chou E Emily D. Brand M Melanie D. Olesiuk C Christine C. Domingo H Hunter J. Little T Thomas T. Goodman J Jacqueline L. Posy J Jasmin Gonzalez T Terrina L. Bayone J Jessica Sparks E Ebony N. Gary Z Zhi Xiang N Nicholas J. Tursi (Vaccine and Immunotherapy Center, The Wistar Institute) C Casey E. Hojecki H Hildegund C. J. Ertl D David B. Weiner (Vaccine and Immunotherapy Center, The Wistar Institute) I Irafasha C. Casmil A Anna K. Blakney B Brandon Essink (Meridian Clinical Research, Omaha, NE) G Guillermo Somodevilla N Nathaniel S. Wang A Andrew J. Geall Z Zelanna Goldberg P Parinaz Aliahmad